Edition:
United States

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.33EUR
23 Apr 2018
Change (% chg)

€0.02 (+1.76%)
Prev Close
€1.31
Open
€1.30
Day's High
€1.33
Day's Low
€1.28
Volume
9,340,769
Avg. Vol
19,348,218
52-wk High
€1.62
52-wk Low
€0.28

Select another date:

Thu, Mar 15 2018

BRIEF-Pharming Enters Euronext Amsterdam SmallCap-Index (AScX)

* PHARMING ENTERS THE EURONEXT AMSTERDAM SMALLCAP-INDEX (ASCX) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharming Group Q4 Revenues From Product Sales OF EUR 32.7 Mln, Up 26 Pct Vs. Q3

* DELIVERED REVENUE FOR FULL YEAR OF EUR 89.6 MILLION (US$101.2 MILLION) - AN INCREASE OF 464% ON 2016

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds

* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH

BRIEF-Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds

* PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS

BRIEF-Pharming Submits License Application to FDA for Ruconest

* PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2

* ‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​

Select another date: